Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Oncology

Journal Scan / Research · February 14, 2019

Immunogenicity and Safety of the Adjuvanted Recombinant Zoster Vaccine in Patients With Solid Tumors Receiving Chemotherapy

Cancer

 

Additional Info

Cancer
Immunogenicity and Safety of the Adjuvanted Recombinant Zoster Vaccine in Patients With Solid Tumors, Vaccinated Before or During Chemotherapy: A Randomized Trial
Cancer 2019 Feb 01;[EPub Ahead of Print], P Vink, I Delgado Mingorance, C Maximiano Alonso, B Rubio-Viqueira, KH Jung, JF Rodriguez Moreno, E Grande, D Marrupe Gonzalez, S Lowndes, J Puente, H Kristeleit, D Farrugia, SA McNeil, L Campora, E Di Paolo, M El Idrissi, O Godeaux, M López-Fauqued, B Salaun, TC Heineman, L Oostvogels

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading